

Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use

Alessandro Cuomo¹, Angelo Bianchetti², Annachiara Cagnin³, Domenico De Berardis⁴, Ignazio Di Fazio⁵, Raffaele Antonelli Incalzi⁶, Camillo Marra⁷, Francesca Neviani⁸, Ferdinando Nicoletti⁹

¹ University of Siena School of Medicine, Siena, Tuscany, Italy; ² Medicine and Rehabilitation Department, Istituto Clinico 'S. Anna' Hospital, Brescia, Italy; Associazione Italiana di Psicogeriatrica (AIP), Brescia, Italy; Società Italiana di Geriatria e Gerontologia (SIGG), Firenze, Italy; ³ Department of Neurosciences, Sciences NPSRR, University of Padua Medical School, Padua, Italy; ⁴ National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, 'G. Mazzini' Hospital, Teramo, Italy; ⁵ Ospedale Richiedei, Palazzolo (BR), Italy; ⁶ Gerontology Unit, Campus Bio Medico University and Teaching Hospital, Rome, Italy; ⁷ Memory Clinic, Neurology Department, Catholic University of Rome, Italy; ⁸ Department of Geriatrics, Nuovo Ospedale Civile 'S. Agostino Estense', Modena and Reggio Emilia University, Modena, Italy; ⁹ Department of Biomedical and Biotechnological Sciences, University of Catania, Italy

Received: November 20, 2020

Accepted: February 3, 2021

Correspondence

Alessandro Cuomo

University of Siena School of Medicine, viale
Bracci 16, 53100 Siena, Italy

E-mail: alessandrocuomo86@gmail.com

Conflict of interest

The Authors declare no conflict of interest

How to cite this article: Cuomo A, Bianchetti A, Cagnin A, et al. Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use. Journal of Gerontology and Geriatrics Online First 2021;Mar 31. <https://doi.org/10.36150/2499-6564-N320>

© Copyright by Società Italiana di Gerontologia e Geriatria (SIGG)



OPEN ACCESS

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

Trazodone is indicated for the treatment of Major Depressive Disorder (MDD), often associated with anxiety, insomnia, agitation, nervousness, or irritability.

The aim of this review was to summarise the pharmacological properties of trazodone in improving depressive symptoms in elderly patients and in patients with neurological comorbidities, for whom secondary depression is often present.

Five different pharmaceutical formulations of trazodone are available: intravenous or intramuscular liquid solution, immediate-release tablets (I.R.), oral drops, prolonged-release tablets (P.R.), and extended-release Contramid® tablets (COAD). The initial dose of trazodone should range from 75 to 100 mg/day. For COAD formulation, the starting recommended dose is 150 mg once daily. In elderly patients, trazodone may be administered at very low dosages (25-50 mg/day for I.R. formulation, and 50-100 mg for the P.R. or E.R. formulations). The maximum daily dose should not exceed 300 mg/day, split over two administrations across the day.

In elderly patients, trazodone has reported excellent results, keeping high-quality standards for safety and tolerability. It can help to improve insomnia and anxiety without resorting to benzodiazepines. In patients with neurological conditions, trazodone helps to treat anxiety-depressive symptoms. In patients with Alzheimer's disease or frontotemporal dementia, trazodone can help to handle behavioural symptoms, also acting as a putative neuroprotective agent.

Trazodone is well tolerated. Somnolence/sedation, dizziness, constipation, and blurred vision are common side effects with an incidence slightly greater than 5%. Orthostatic hypotension and headache are relatively common side effects.

The great availability of formulations allows to personalise trazodone administration according to patient profile characteristics.

Key words: trazodone, major depressive disorder, neurological disorder, geriatric population, insomnia

INTRODUCTION

Trazodone is indicated for the treatment of depression and has been shown efficacious in reducing most symptoms associated with depression ¹⁻³.

The peculiar multifunctional pharmacological profile of trazodone explains its efficacy to improve Major Depressive Disease (MDD), a very heterogeneous condition often associated with anxiety, insomnia, agitation, nervousness, or irritability ^{2,4-6}. To diagnose MDD, an individual must be experiencing five or more symptoms (Tab. I) during the same 2-week period. At least one of the symptoms should be either depressed mood or anhedonia ⁷.

All DSM criterion symptoms, except depressed mood, comprise at least two sub-symptoms, and three of the criterion symptoms (sleep, weight/appetite, psychomotor) can be met by either increases or decreases. Therefore, up to 16,400 possible symptom profiles can generate a diagnosis of MDD ⁸. Furthermore, the transdiagnostic determinants and the DSM-5 specifiers (e.g., with anxious distress or with psychotic features) generate a much higher number of clinically relevant profiles ^{9,10}.

Recent studies investigated the efficacy of particular antidepressants in improving symptoms for specific phenotypical profiles, thus showing how the selection of the best drug for a given cluster could be the new personalised approach for depression ¹¹.

In such context, trazodone can represent an efficacious treatment for the geriatric population.

In the elderly population, the risk of depression is high¹². In patients with one or more chronic illnesses or disabling conditions, secondary depression can be induced by pharmacological treatments¹³. Furthermore, depression can aggravate the chronic disease and *vice versa* could be exacerbated by the chronic disease itself. For

example, heart disease and depression can be reciprocally worsened.

Symptoms of depression in the elderly differ from those in the young. Sleep disturbance and agitation may prevail in elderly patients. Other symptoms, as confusion or impaired attention, may be misinterpreted as a neurological disorder (i.e., Alzheimer's disease).

In patients with neurological conditions, secondary depression is common. Epilepsy, stroke, Parkinson's disease, and other neurological illnesses reported a high prevalence of secondary depression. Sleep disorder, fatigue, poor concentration, or disturbed appetite are also present. Antidepressants may improve symptoms, quality of life, and overall survival in patients with neurological disorders ¹⁴. The aim of this narrative review was to summarise the pharmacological properties of trazodone in elderly patients and patients with neurological comorbidities. Moreover, this work also investigated trazodone efficacy on some specific symptoms as sleep disturbance, anxiety, agitation, and substance abuse. Two case reports were reported.

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS

Trazodone is a Serotonin Receptor Antagonist and Reuptake Inhibitor (SARI) ² due to its affinity profile for the serotonin reuptake transporter (SERT) and serotonin receptors ¹⁵. Trazodone behaves as a potent antagonist of 5-HT_{2A} and 5-HT_{2B} receptors, an antagonist of 5-HT_{1D}, 5-HT_{2C}, α_{1A} , α_{2C} H₁ receptors with moderate affinity, a partial agonist of 5-HT_{1A} receptors, and an inhibitor of SERT (Tab. II). At therapeutic dose, trazodone has no activity at muscarinic cholinergic receptors, dopamine receptors, and dopamine or noradrenaline transporters. Similar to other antidepressants, it inhibits serotonin reuptake ¹⁶. The multi-target profile of trazodone provides the following clinical advantages:

- 1 The partial agonist activity at 5-HT_{1A} receptor may facilitate desensitisation of 5-HT_{1A} receptors in serotonergic projecting neurons of the dorsal raphe nucleus, thereby allowing a rapid antidepressant action¹⁷ and may contribute to the anxiolytic activity of trazodone, as suggested by preclinical studies ¹⁸;
- 2 5-HT_{2A} and 5-HT_{2C} receptor blockade may limit the incidence of sexual dysfunction, usually associated with serotonergic drugs ¹⁹;
- 3 Antagonism at 5-HT_{2A}, α_{1A} , and H₁ receptors confer sedative and hypnotic properties ^{20,21}. Trazodone may treat the symptoms of hypoactive sexual desire disorder and antidepressant-associated sexual dysfunction because of its 5-HT₂ antagonism ²²⁻²⁴;

Table I. MDD Symptoms.

Depressed mood most of the day
Diminished interest or loss of pleasure in almost all activities most of the day (anhedonia)
Significant weight change or appetite decrease or increase nearly every day
Sleep disturbance (insomnia or hypersomnia)
Psychomotor agitation or retardation nearly every day
Fatigue or loss of energy nearly every day
Feelings of worthlessness nearly every day
Diminished ability to think or concentrate; indecisiveness nearly every day
Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or specific plan for committing suicide

Table II. Pharmacodynamic profile of trazodone.

Receptor	K _i (nM)	Effects
SERT	367.3	Antagonist
5-HT _{1A}	118	Partial agonist
5-HT _{1D}	106	Antagonist
5-HT _{2A}	35.8	Antagonist
5-HT _{2B}	78.4	Antagonist
5-HT _{2C}	223.9	Antagonist
α_{1A}	153	Antagonist
α_{2C}	155	Antagonist
H ₁	220	Antagonist

Source data: Psychoactive Drug Screening Program (PDSP) database. K_i values are inversely proportional to the binding affinity of the drug for the target

- 4 The moderate affinity for 5-HT_{2C} and H₁ receptors may limit the risk of weight gain.

PHARMACOKINETICS

To date, at least five different pharmaceutical preparations of trazodone are available in the European Union (E.U.) or USA markets: 1) intravenous or intramuscular liquid solution, 2) immediate-release tablets (I.R.), 3) oral drops, 4) prolonged-release tablets (P.R.), and 5) extended-release Contramid® tablets (COAD).

Some pharmacokinetic parameters (C_{max}, T_{max}, and elimination half-life t_{1/2}) could differ according to the drug formulation (Table III). Trazodone is extensively metabolised by CYP-450 3A4. More than 99% of bioavailable trazodone is converted *via* oxidative cleavage to meta-chlorophenylpiperazine (mCPP), an active metabolite further metabolised by CYP2D6²⁵. Meta-chlorophenylpiperazine concentrations *in vivo* range from 1 to 20%

of those of the parent drug²⁶. Thus, the contribution of mCPP to the overall clinical activity is unclear. Trazodone has shown a serum protein binding of 90-95%, resulting in a bloodstream free fraction of 5-10%. Elimination predominantly follows the renal route. Trazodone pharmacokinetics approximates a two-compartment distribution model²⁰. Because of its hydrophobic features, this compound easily binds to fat tissues and crosses cell membranes²⁷. The oral bioavailability of trazodone is mostly affected by food. C_{max} value increases by 86% when the drug is administered with food²⁸.

DOSAGES

GENERAL RECOMMENDATIONS

According to EMA guidelines, the initial dose of trazodone should range from 75 to 100 mg/day, administered in a single dose before bedtime. Dosage should be adjusted accordingly to clinical responses, up to 300 mg/day, split over two administrations across the day. Trazodone reaches the steady-state levels in about two days. The recommended starting dose of COAD is 150 mg once daily in adults. The dose may be increased by 75 mg/day every three days (i.e., start 225 mg on Day 4 of therapy). The maximum daily dose should not exceed 300 mg²⁹.

FORMULATIONS

The availability of different formulations (Table III) ensures the efficacy of trazodone in a wide range of

Table III. Pharmacokinetics.

Trazodone	Formulations	C _{max}	T _{max}	t _{1/2}	Food interaction
TZ _{IR}	50 mg tablets 100 mg tablets 25 mg/ml drops 60 mg/ml drops	1.2-1.6 µg/ml	1 h (1.5 h elderly)	6.6 h (9-11 h at steady state)	Slow absorption
TZ _{IV/IM}	50 mg/5 ml solution for injection	NA	Immediate	6-8-h	No effect
TZ _{PR} film-coated	75 mg tablets 150 mg tablets	0.7-1.2 µg/mL	4 h	12 h	No effect
TZ _{COAD}	150 mg tablets 300 mg tablets	~ 1.5 mg/L (steady state) 2 ± 0.635 µg/mL	7.57 ± 2.3 h	10 h	Increased absorption Administration of TZ _{COAD} 300 mg once daily provides equivalent steady-state exposure to, with a lower C _{max} than, TZ _{IR} 100 mg given 3 times a day. A high-fat meal increases C _{max} , but there is no substantial effect on AUC.

TZ: trazodone; IR: immediate-release; IV: intravenous; IM: intramuscular; PR: prolonged-release; COAD: extended-release Contramid®

clinical scenarios. For example, the immediate-release (I.R.) formulation (available as tablets or liquid drops) reaches maximum blood levels in about an hour, ensuring rapid effects for symptoms like insomnia²². The relatively short elimination half-life (6h) reduces the risk of morning drowsiness³⁰. The prolonged-release (P.R.) formulation is characterised by a film coating, which ensures slow release into the bloodstream. The extended-release (COAD) formulation provides an even more gradual and continuous absorption of the drug into the bloodstream. It allows a simplified once-a-day prescription schedule, thus enhancing adherence, improving tolerability, and avoiding see-sawing blood concentration patterns³⁰.

REAL WORD ISSUES & EXPERT OPINION: IDEAL TARGETED DISORDERS FOR TRAZODONE

DEPRESSION IN ELDERLY PATIENTS

Trazodone is clinically useful in elderly patients, including people with agitated behaviour, because of its specific anxiolytic and sleep normalising effect and excellent safety and tolerability³¹. In elderly patients, a very low starting dose is recommended, usually no more than 25-50 mg/day for the I.R. formulation or 50-100 mg for the P.R. or E.R. formulations. However, ageing does not significantly impair liver metabolism by CYP3A4, while the reduced renal clearance may increase trazodone blood concentrations³².

When treating elderly patients, the once-a-day COAD formulation may be the best choice to rapidly reach therapeutic doses while minimising side effects (i.e., orthostatic hypotension). The liquid formulation may be preferred if dysphagia or other difficulties in administration are present. Drops may represent an advantage when small dosage changes are necessary. The rapid peak effect of the I.R. formulations (drops or tablets) also enables appropriate insomnia management. In our experience, most elderly depressed patients improve with doses as low as 100 mg/day. Finally, the dual action of trazodone on anxiety and depression is particularly useful to reduce benzodiazepines, which are burdened by several risks in elderly patients.

DEPRESSION WITH NEUROLOGICAL COMORBIDITIES

Special populations such as depressed elderly patients may also be at high risk of dementia and cognitive impairment, for which depression has been reported as a risk factor or an early harbinger³³. Trazodone helps to treat anxiety-depressive symptoms associated with subcortical dementias, Parkinsonism, and movement or behavioural disorders. It may be efficacious in treating

behavioural symptoms of Alzheimer's disease³⁴ and frontotemporal dementia³⁵. Interestingly, trazodone might cause neuroprotection by inhibiting the pancreatic endoplasmic reticulum kinase and eukaryotic initiation factor-2a (PERK/EIF-2a) unfolded protein response pathway³⁶. Sustained activation of this pathway, which is associated with Alzheimer's disease, frontotemporal dementia, and other neurodegenerative disorders characterised by protein misfolding³⁷⁻³⁹, causes translation repression, with ensuing neurodegeneration³⁶. This unique property of trazodone suggests that this drug might be particularly valuable for treating depression associated with insomnia in patients with chronic neurodegenerative disorders, particularly in the early phases of neurodegeneration. In neurodegenerative disorders, trazodone behaves as a putative neuroprotective agent because it may promote the secretion of neurotrophic factors from cultured human astrocytes⁴⁰.

Furthermore, the absence of anticholinergic effects of trazodone is a further advantage in treating depression associated with Alzheimer's disease. The use of tricyclic antidepressant drugs and several antipsychotic agents in Alzheimer's disease is seriously limited by the anticholinergic activity of these drugs, which may further impair cognition^{41,42}. On the contrary, recent retrospective analysis has reported an association between trazodone treatment and delayed cognitive decline in a sample of patients affected by Alzheimer's disease⁴³.

DEPRESSION WITH SLEEP DISTURBANCES

Insomnia is a condition that could significantly impact daytime activities because of a change of the sleeping pattern (difficulties with falling and staying asleep or waking too early). While primary insomnia has an unknown aetiology, secondary insomnia is usually induced by psychiatric or physical conditions or some external factors. There is strong evidence about the effectiveness of trazodone in the treatment of both primary and secondary insomnia⁴⁴. Trazodone improves sleep mainly by increasing total sleep time, enhancing delta sleep entry, and decreasing the number of night-time awakenings⁴⁵. It maintains these qualities in healthy and depressed-insomniac patients^{46,47}. However, the antidepressant efficacy of trazodone seems unrelated to the severity of insomnia at baseline². Roth et al. (2011) observed that a 50 mg dose of trazodone required one week to ameliorate the delta sleep phase, while 100 mg showed a positive effect after 1-2 days⁴⁸.

DEPRESSION IN COMORBIDITY WITH OTHER CONDITIONS

Agitation and behavioural disturbances

Depressed patients can manifest verbal or physical aggressiveness, especially if anxiety symptoms,

depressive episodes with mixed features, or comorbid dementia are present^{49,50}. Conversely, elderly patients with dementia who manifest physical or verbal aggression showed a higher prevalence of depression⁵¹. Trazodone inhibits aggressiveness⁵², probably due to its association of a combined serotonergic antidepressant activity and H1 histamine receptor blockade at low doses (i.e., 50-75 mg/day). Other drugs used to treat aggressive behaviour associated with depression (e.g., benzodiazepines) may cause falls, tolerance, physical dependence, and cognition impairment. Moreover, post-stroke patients often display depressive symptoms with emotional and behavioural changes such as anger, hostility, and impulsivity⁵³. Of note, trazodone showed beneficial effects at 300 mg/die in post-stroke depression⁵⁴.

Preclinical findings have hypothesised that trazodone may restrain L-DOPA-induced dyskinesia and psychosis-like behaviours in Parkinson's disease⁵⁵. Trazodone administration was also beneficial in a sample of bipolar inpatients affected by psychomotor agitation⁵⁶. Other studies showed a good efficacy of trazodone in patients with agitation⁵⁷ and antipsychotic-induced akathisia⁵⁸.

Depression and anxiety

A large body of evidence supports the value of trazodone for treating generalised anxiety disorder⁵⁹ or post-traumatic stress disorder (PTSD)⁶⁰. In both conditions, trazodone improved sleep disturbances⁵. It may be of particular help in patients with anxiety disorders who are at risk for benzodiazepine abuse⁵.

Depression and substance abuse induced sleep disturbance

The reward deficiency syndrome that includes both dysphoric and depressive symptoms may appear after cocaine detoxification. A 9-patient study about X.R. trazodone formulation for the treatment of cocaine withdrawal symptoms has hypothesised that trazodone may improve the reduction of craving and reduce psychological symptoms, although its efficacy to avoid early relapse should be further confirmed⁶¹.

Depression is commonly represented in substance abuse and usually unrecognised. Proper diagnosis of mood disturbance could prevent episodes of relapse and reduce suicide rates in this patient population. It would be necessary for routine clinical practice to recognise if a patient has primary or substance-induced depression to avoid treatment delay⁶².

Sleep disturbance is frequent during alcohol withdrawal. A randomised, double-blind placebo-controlled trial showed that low doses of trazodone could improve sleep quality during alcohol withdrawal. However, the effect was lost once trazodone was discontinued⁶³.

SAFETY AND TOLERABILITY

Trazodone is well tolerated in MDD patients^{2,22}. The most common side effects are somnolence/sedation, dizziness, constipation, blurred vision. The incidence of these side effects is greater than 5% and is double that of placebo⁶⁴. Other bothersome or relatively common side effects include orthostatic hypotension and headache^{2,22,65}. Orthostatic hypotension may be more severe if an antihypertensive agent is associated. In the geriatric population, falls may occur more frequently^{66,67}.

Priapism is a rare adverse effect, likely due to α -adrenergic receptor blockade^{66,68,69}. Trazodone should be used with caution to reduce the risk of priapism in patients affected by multiple myeloma, sickle cell anaemia, hypercoagulable states, leukaemia, autonomic nervous system dysfunctions, and anatomical deformation of the penis (e.g., Peyronie's disease, angulation, or cavernosal fibrosis), or in combination with SSRIs, cocaine, or atypical antipsychotics^{2,70}.

HOW TO MANAGE THE ADVERSE EFFECTS OF TRAZODONE

Orthostatic hypotension and dizziness

Trazodone has an excellent cardiovascular safety profile⁷¹, although mild orthostatic hypotension can occur. Therefore, it is recommended to measure blood pressure before administration and advise the patient to remain seated or in bed for at least 30 minutes after administration and not to change position too quickly. A recent investigation on a small sample of real-world elderly depressed patients reported no significant associations between QTc variations and trazodone administration⁷². Trazodone may also cause dizziness, which is a consequence of α -adrenergic receptor blockage, and usually occurs when large doses of the drug are taken on an empty stomach⁶⁵. Due to the inhibition of small muscle contraction, patients may have a subjective feeling of losing balance and dizziness in more severe cases. In such cases, patients should lay down, rest, and avoid rapid movements. Proper hydration is recommendable, avoiding caffeine, nicotine, or alcohol⁷³.

Headache

Trazodone may induce headache. This effect is mediated by the active metabolite, mCPP, which, as opposed to trazodone, acts as an agonist at various serotonin receptors and may also enhance serotonin release⁷⁴. Trazodone-induced headaches may not respond to conventional analgesics, and, therefore, can only be managed by suspending the treatment⁷⁵.

Sedation

Sedation during daytime sleepiness is a common adverse effect of trazodone⁷⁶. Daytime sleepiness

might contribute to fatigue, decreased quality of life, and increased risk of occupational or car accidents ⁷⁷. Dosage adjustments, change in trazodone formulation (e.g., switching to the I.R. formulation, administered in the evening), and behavioural interventions, such as going to bed early ⁷⁸, can improve symptomatology.

Gastrointestinal symptoms

Nausea and other gastrointestinal symptoms may occur if the agent is taken at high doses on empty stomach. Thus, taking trazodone with food is recommended ⁶⁵. For dry mouth, the use of oral lubricating gels, artificial saliva, or chewing gum might help to enhance salivation ⁷⁹.

Overdose

Trazodone is a safe drug. Doses of 500 mg per kg are lethal for experimental animals. In contrast, doses as high as 10 g may not cause death in humans ⁶⁵. High doses of trazodone may seldom cause serotonin syndrome, a life-threatening condition due to serotonin accumulation ⁸⁰. The most common systems involved in trazodone overdose are respiratory, cardiovascular, nervous, and gastrointestinal systems ⁸¹.

At toxic blood concentrations, trazodone may cause prolongation of Q.T. interval and torsade de pointes. Cases of life-threatening cardiac arrhythmias have been reported even at regular doses. Concomitant use of trazodone with drugs known to prolong the Q.T. interval or causing cardiac toxicity should be avoided ².

Contraindications - warnings

Trazodone should not be used in combination with monoamine oxidase inhibitors (MAOIs). Caution is needed when trazodone is co-administrated with drugs that increase serotonin levels for the potential risk of serotonin syndrome ⁸².

In patients with liver failure, trazodone should be avoided ⁸³. It should not be used during intoxication with alcohol or hypnotic agents or in patients with myocardial infarction ⁸⁴.

CASE SCENARIOS

CASE 1: DEPRESSION IN PATIENTS WITH NEUROLOGICAL DISORDERS

A 51-year-old woman, divorced, without sons, was diagnosed with multiple sclerosis. Since she lost her job, she experienced a depressed mood, sleeping problems, apathy, difficulty performing daily activities, and increased appetite. She also complained of anxiety, aggravation, restlessness, muscle tension, poor

concentration, and fatigue. Her primary care physician prescribed her clonazepam, which she gradually increased up to 8 mg/day without consulting her doctor. After two years, since she reported depressed mood, severe anxiety, poor concentration, poor memory, increased appetite, and suicidal thoughts, she was hospitalised. X.R. trazodone 150 mg, to be taken before bedtime, was prescribed. Clonazepam was gradually decreased to 6 mg on day 1, 4 mg on day 2, 3 mg on days 3 and 4, 2 mg on days 6 and 7, and 1 mg on days 8 and 9, followed by discontinuation. During hospitalisation, the patient also received intensive psychotherapy. After three days, trazodone was increased to 225 mg, and after another three days, the dose was further increased to 300 mg. She showed a gradual improvement in mood, anxiety, and cognitive functions. Trazodone was also combined with prolonged-release quetiapine to improve mood and anxiety. Quetiapine was started at 50 mg, to be taken in the morning, and gradually increased up to 200 mg, always to be taken in the morning. Two weeks after discharge from the hospital, the patient complained about moderate daytime sleepiness, which improved after discontinuing quetiapine. COAD trazodone was continued at 300 mg in the evening. Excellent results were reported.

CASE 2: DEPRESSION IN A GERIATRIC PATIENT WITH COGNITIVE IMPAIRMENT

A 75-year-old widow with three sons showed mild attention deficit and difficulty planning actions, abstracting thoughts, and finding words and names for commonly used objects. In the following two years, her condition deteriorated significantly: memory loss, difficulty recognising familiar people and places, disorientation, inability to acquire new information, and a gradual tendency to neglect her hygiene and nutrition were registered. Therefore, she was admitted to an assisted health residence. Later, she experienced apathy, loss of interest, refusal to get out of her bed, reluctance to eat, insomnia, anxiety, depressed mood, crying spells, and pessimistic thoughts. After a thorough assessment, she was diagnosed with depression, comorbid to cognitive impairment. So far, memantine at the dose of 10 mg/day was administered. Later, COAD trazodone 150 mg, half tablet to be taken in the evening, was prescribed. After three days, her insomnia and anxiety improved, and no side-effects were reported. She started to eat again. COAD trazodone was increased to 1 tablet in the evening with a progressive and clear-cut improvement of sleep, anxiety, mood, appetite, and interests. After about five weeks of trazodone treatment, the patient was completely free of depressive symptoms.

CONCLUSIONS

Major depressive disorder is a great public health challenge, the leading worldwide cause of disability. The complexity and heterogeneity of this condition have always been the object of clinicians. Many efforts have been made to identify antidepressants and personalised formulations in improving symptoms according to the different patient profiles. There is evidence that a range of depressive patient profiles, including elderly patients and those with underlying neurological conditions, sleep disturbance, agitation, or substance abuse, may benefit from trazodone.

The efficacy, safety, and tolerability of trazodone are widely proven. Different formulations allow personalised treatments, thus improving specific symptoms associated with depression MDD, like insomnia, anxiety, agitation, or nervousness. The COAD formulation offers the advantage of once-a-day administration and the possibility to start with a dose (150 mg) that is already potentially effective for depression, along with a steady, gradual release of the medication in the bloodstream throughout 24 hours. The PR formulation offers the advantage of an evening administration (up to 150 mg) for patients (e.g., those with middle and late awakenings) who need drug exposure during the night and a maximum blood concentration at approximately 4 hours from drug intake. The I.R. formulation offers the advantage of reaching the maximum blood concentration after 1-2 hours, and this is particularly valuable for depressive patients with initial-early insomnia. Intravenous and intramuscular formulations have immediate or quick absorption, respectively. These advantages are particularly useful in patients with depression and psychomotor agitation. Intravenous and intramuscular formulations help patients with poor adherence or inability (e.g., post-surgery) to take oral medications. Trazodone displays a good tolerability profile, with a low risk for weight gain, sexual dysfunction, and anticholinergic effects such as dry mouth, constipation, and urinary retention. Finally, the PERK/EIF-2a pathway inhibition suggests trazodone as a potential neuroprotective activity in chronic neurodegenerative disorders characterised by protein misfolding, such as Alzheimer's disease, in which comorbid depression complicates the management of patients.

References

- Golden RN, Dawkins K, Nicholas L. Trazodone and nefazodone. In: Schatzberg AF, Nemeroff CB, Eds. *The American psychiatric publishing textbook of psychopharmacology*, Fourth Ed. Washington, D.C.: American Psychiatric Publishing, Inc., 2009, p. 403.
- Fagiolini A, Comandini A, Catena Dell'Osso M, et al. Re-discovering trazodone for the treatment of major depressive disorder [published correction appears in *CNS Drugs*. 2013;27:677]. *CNS Drugs* 2012;26:1033-49. <https://doi.org/10.1007/s40263-012-0010-5>
- Stahl SM. Mechanism of action of trazodone: a multi-functional drug. *CNS Spectr* 2009;14:536-46. <https://doi.org/10.1017/s1092852900024020>
- Goracci A, Forgione RN, De Giorgi R, et al. Practical guidance for prescribing trazodone extended-release in major depression. *Expert Opin Pharmacother* 2016;17:433-41. <https://doi.org/10.1517/14656566.2016.1133587>
- Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. *Expert Opin Pharmacother* 2012;13:1707-17. <https://doi.org/10.1517/14656566.2012.699523>
- Bossini L, Coluccia A, Casolaro I, et al. Off-label trazodone prescription: evidence, benefits and risks. *Curr Pharm Des* 2015;21:3343-51. <https://doi.org/10.2174/1381612821666150619092236>
- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*, Fifth Ed. Washington, DC: American Psychiatric Association 2013.
- Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. *J Affect Disord* 2015;172:96-102. <https://doi.org/10.1016/j.jad.2014.10.010>
- Park SC, Kim YK. Diagnostic issues of depressive disorders from kraepelinian dualism to the Diagnostic and statistical manual of mental disorders, Fifth Ed. *Psychiatry Investig* 2019;16:636-44. <https://doi.org/10.30773/pi.2019.09.07>
- Fang Y, Wu Z. Advance in diagnosis of depressive disorder. *Adv Exp Med Biol* 2019;1180:179-91. https://doi.org/10.1007/978-981-32-9271-0_9
- Chekroud AM, Gueorguieva R, Krumholz HM, et al. Re-evaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. *JAMA Psychiatry* 2017;74:370-8. <https://doi.org/10.1001/jamapsychiatry.2017.0025>
- <https://www.cdc.gov/aging/mentalhealth/depression.htm>
- <https://www.nia.nih.gov/health/depression-and-older-adults>
- Bassiony MM. Depression and neurological disorders. *Neurosciences* 2009;14:220-9.
- Khouzam HR. A review of trazodone use in psychiatric and medical conditions. *Postgrad Med* 2017;129:140-8. <https://doi.org/10.1080/00325481.2017.1249265>
- Liu B, Liu J, Wang M, et al. From serotonin to neuroplasticity: evolution of theories for major depressive disorder. *Front Cell Neurosci* 2017;11:305. <https://doi.org/10.3389/fncel.2017.00305>
- Montalbano A, Mlinar B, Bonfiglio F, et al. Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT_{1A} receptor partial agonism and α 1-adrenoceptor antagonism. *PLoS One* 2019;14:e0222855. <https://doi.org/10.1371/journal.pone.0222855>
- Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its

- active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT_{1A} receptors assessed by [³⁵S]GTPgammaS binding. *J Psychopharmacol* 2005;19:235-41. <https://doi.org/10.1177/0269881105051526>
- 19 Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol* 2009;29:259-66. <https://doi.org/10.1097/JCP.0b013e3181a5233f>
 - 20 Settimo L, Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. *J Psychopharmacol* 2018;32:96-104. <https://doi.org/10.1177/0269881117742101>
 - 21 Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomised, double-blind, and placebo-controlled study. *Am J Geriatr Psychiatry* 2014;22:1565-74. <https://doi.org/10.1016/j.jagp.2013.12.174>
 - 22 Cuomo A, Ballerini A, Bruni AC, et al. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. *Riv Psichiatr* 2019;54:137-49. <https://doi.org/10.1708/3202.31796>
 - 23 Pyke RE. Trazodone in sexual medicine: underused and overdosed? *Sex Med Rev* 2018;8:206-16. <https://doi.org/10.1016/j.sxmr.2018.08.003>
 - 24 Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. *Ther Adv Psychopharmacol* 2018;8:13-23. <https://doi.org/10.1177/2045125317720642>
 - 25 Rotzinger S, Fang J, Baker G.B. Trazodone is metabolised to m-chlorophenylpiperazine by CYP3A4 from human sources. *Drug Metab Dispos* 1998;26:572-5.
 - 26 EMCDDA (https://www.emcdda.europa.eu/attachements.cfm/att_136859_EN_Europol-EMCDDA_Active_Monitoring_Report_mCPP_290307.pdf).
 - 27 Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. *Toxicol In Vitro* 2008;22:457-67. <https://doi.org/10.1016/j.tiv.2007.09.010>
 - 28 FDA (www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022411s000MedR.pdf).
 - 29 FDA (www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf).
 - 30 Fagiolini A, Albert U, Ferrando L, et al. A randomised, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. *Int Clin Psychopharmacol* 2020;35:137-46. <https://doi.org/10.1097/YIC.0000000000000304>
 - 31 Osváth P. Az időskori depresszió és agitáció korszerű kezelése – a trazodon alkalmazásának lehetőségei [Current treatment of depression and agitation in the elderly – clinical use of trazodone]. *Neuropsychopharmacol Hung* 2013;15:147-55. Hungarian.
 - 32 Shi S, Klotz U. Age-related changes in pharmacokinetics. *Curr Drug Metab* 2011;12:601-10. <https://doi.org/10.2174/138920011796504527>
 - 33 Ganguli M. Depression, cognitive impairment and dementia: why should clinicians care about the web of causation? *Indian J Psychiatry* 2009;51(Suppl 1):S29-34.
 - 34 López-Pousa S, Garre-Olmo J, Vilalta-Franch J, et al. Trazodone for Alzheimer's disease: a naturalistic follow-up study. *Arch Gerontol Geriatr* 2008;47:207-15. <https://doi.org/10.1016/j.archger.2007.07.010>
 - 35 Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dement Geriatr Cogn Disord* 2004;17:355-9. <https://doi.org/10.1159/000077171>
 - 36 Halliday M, Radford H, Zents KAM, et al. Repurposed drugs targeting eIF2 α -P-mediated translational repression prevent neurodegeneration in mice. *Brain* 2017;140:1768-83. <https://doi.org/10.1093/brain/awx074>
 - 37 Hoozemans JJ, van Haastert ES, Eikelenboom P, et al. Activation of the unfolded protein response in Parkinson's disease. *Biochem Biophys Res Commun* 2007;354:707-11. <https://doi.org/10.1016/j.bbrc.2007.01.043>
 - 38 Nijholt DA, Nölle A, van Haastert ES, et al. Unfolded protein response activates glycogen synthase kinase-3 via selective lysosomal degradation. *Neurobiol Aging* 2013;34:1759-71. <https://doi.org/10.1016/j.neurobiolaging.2013.01.008>
 - 39 Stutzbach LD, Xie SX, Naj A.C. et al. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. *Acta Neuropathol Commun* 2013;1:31. <https://doi.org/10.1186/2051-5960-1-31>
 - 40 Daniele S, Zappelli E, Martini C. Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes. *J Neuroinflammation* 2015;12:225. <https://doi.org/10.1186/s12974-015-0446-x>
 - 41 Coupland CAC, Hill T, Denning T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. *JAMA Intern Med* 2019;179:1084-93. <https://doi.org/10.1001/jamainternmed.2019.0677>
 - 42 Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. *Expert Opin Drug Saf* 2011;10:751-65. <https://doi.org/10.1517/14740338.2011.579899>
 - 43 La AL, Walsh CM, Neylan TC, et al. Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers. *J Alzheimers Dis*. 2019;67(3):911-921. <https://doi.org/10.3233/JAD-181145>
 - 44 Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. *Innov Clin Neurosci* 2017;14:24-34.
 - 45 Burke AD, Goldfarb D, Bollam P, et al. Diagnosing and treating depression in patients with Alzheimer's disease. *Neurol Ther* 2019;8:325-50. <https://doi.org/10.1007/s40120-019-00148-5>
 - 46 Camargos EF, Pandolfi MB, Freitas MP, et al. Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. *Arq Neuropsiquiatr* 2011;69:44-9. <https://doi.org/10.1590/s0004-282x2011000100010>

- 47 Suzuki H, Yamadera H, Nakamura S, et al. Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature. *J Nippon Med Sch* 2002;69:333-41. <https://doi.org/10.1272/jnms.69.333>
- 48 Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. *J Sleep Res* 2011;20:552-8. <https://doi.org/10.1111/j.1365-2869.2011.00928.x>
- 49 Verdolini N, Perugi G, Samalin L, et al. BRIDGE-II-Mix Study Group. Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features. *Acta Psychiatr Scand* 2017;136:362-72. <https://doi.org/10.1111/acps.12777>
- 50 Lyketsos CG, Steele C, Galik E, et al. Physical aggression in dementia patients and its relationship to depression. *Am J Psychiatry* 1999;156:66-71.
- 51 Menon AS, Gruber-Baldini AL, Hebel JR, et al. Relationship between aggressive behaviors and depression among nursing home residents with dementia. *Int J Geriatr Psychiatry* 2001;16:139-46.
- 52 Saletu-Zyhlarz GM, Anderer P, Arnold O, et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. *Neuropsychobiology* 2003;48:194-208. <https://doi.org/10.1159/000074638>
- 53 Kim JS. Post-stroke mood and emotional disturbances: pharmacological therapy based on mechanisms. *J Stroke* 2016;18:244-55. <https://doi.org/10.5853/jos.2016.01144>
- 54 Raffaele R, Rampello L, Vecchio I, et al. Trazodone therapy of the post-stroke depression. *Arch Gerontol Geriatr* 1996;22(Suppl 1):217-20. [https://doi.org/10.1016/0167-4943\(96\)86939-1](https://doi.org/10.1016/0167-4943(96)86939-1)
- 55 Hamadjida A, Nuara SG, Gourdon JC, et al. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. *J Neural Transm (Vienna)* 2018;125:1355-60. <https://doi.org/10.1007/s00702-017-1830-8>
- 56 Ballerio M, Politi P, Crapanzano C, et al. Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder. *Neuro Endocrinol Lett* 2018;39:205-8.
- 57 Glass OM, Hermida AP, Hershenberg R, et al. Considerations and current trends in the management of the geriatric patient on a consultation-liaison service. *Curr Psychiatry Rep* 2020;22:21. <https://doi.org/10.1007/s11920-020-01147-2>
- 58 Stryer R, Rosenzwaig S, Bar F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. *Clin Neuropharmacol* 2010;33:219-22. <https://doi.org/10.1097/WNF.0b013e3181ee7f63>
- 59 Gale CK. The treatment of generalised anxiety disorder. A systematic review. *Panminerva Med* 2002;44:283-6.
- 60 Maher MJ, Rego SA, Asnis GM. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. *CNS Drugs* 2006;20:567-90.
- 61 Maremmani I, Spera V, Maremmani A, et al. Is trazodone contraindicated useful in inducing patients to refrain from using cocaine after detoxification, so avoiding early relapse? A case series. *Addict Disord Their Treat* 2019;18:105-12. <https://doi.org/10.1097/ADT.0000000000000157>
- 62 Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. *Dialogues Clin Neurosci* 2015;17:181-190.
- 63 Friedmann PD, Rose JS, Swift R, et al. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. *Alcohol Clin Exp Res* 2008;32:1652-60. <https://doi.org/10.1111/j.1530-0277.2008.00742.x>
- 64 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf
- 65 Schatzberg AF, DeBattista C. Schatzberg's manual of clinical psychopharmacology, ninth edition. Washington DC: American Psychiatric Association Publishing 2019, pp 96-105.
- 66 Kaplan BJ, Sadock VA. Kaplan and Sadock's pocket handbook of clinical psychiatry, Sixth Ed. Baltimore (P.A.): Wolters Kluwer 2018.
- 67 Farrell B, Shamji S, Ingar N. Reducing fall risk while managing pain and insomnia: addressing polypharmacy in an 81-year-old woman. *Can Pharm J (Ott)* 2013;146:335-41. <https://doi.org/10.1177/1715163513504529>
- 68 Saenz de Tejada I, Ware JC, Blanco R, et al. Pathophysiology of prolonged penile erection associated with trazodone use. *J Urol* 1991;145:60-4.
- 69 Warner MD, Peabody CA, Whiteford HA, et al. Trazodone and priapism. *J Clin Psychiatry* 1987;48:244-5.
- 70 Sood S, James W, Bailon MJ. Priapism associated with atypical antipsychotic medications: a review. *Int Clin Psychopharmacol* 2008;23:9-17. <https://doi.org/10.1097/YIC.0b013e3282f1c1ef>
- 71 Alvarez W Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. *Pharmacotherapy* 2003;23:754-71. <https://doi.org/10.1592/phco.23.6.754.32185>
- 72 Armstrong SEM, Brown HK, Shorey C, et al. No association between trazodone and corrected-qt prolongation in older adults. *J Clin Psychopharmacol* 2019;39:528-30. <https://doi.org/10.1097/JCP.0000000000001102>
- 73 NHS (<https://www.nhs.uk/conditions/dizziness>).
- 74 Maes M, Westenberg H, Van Doolaege E, et al. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. *J Clin Psychopharmacol* 1997;17:358-64.
- 75 Chen HC, Tsai SJ. Trazodone-induced severe headache. *Psychiatry Clin Neurosci* 2011;65:681-2. <https://doi.org/10.1111/j.1440-1819.2011.02276.x>
- 76 Jaffer KY, Chang T, Vanle B, et al. Trazodone for Insomnia: a systematic review. *Innov Clin Neurosci* 2017;14:24-34.

- ⁷⁷ Murray B. A practical approach to excessive daytime sleepiness: a focused review. *Can Respir J* 2016; 2016. <https://doi.org/10.1155/2016/4215938>
- ⁷⁸ NHS (<https://www.nhs.uk/conditions/excessive-daytime-sleepiness-hypersomnia>).
- ⁷⁹ Daly C. Oral and dental effects of antidepressants. *Aust Prescr* 2016;39:84. <https://doi.org/10.18773/austprescr.2016.035>
- ⁸⁰ Gaffney RR, Schreiber IR. Serotonin Syndrome in a patient on trazodone and duloxetine who received fentanyl following a percutaneous liver biopsy. *Case Rep Gastroenterol* 2015;9:132-6.
- ⁸¹ Levine M, Ruha A-M. Antidepressants. In: Walls RM, Hockberger RS, Gausche-Hill M, Eds. *Rosen's emergency medicine: concepts and clinical practice*. 9th Ed. Philadelphia, PA: Elsevier 2018, chap. 146.
- ⁸² Shin JJ, Saadabadi A. Trazodone. [Updated 2020 May 28]. In: StatPearls [Internet]. Treasure Island (F.L.): StatPearls Publishing 2020;Jan.
- ⁸³ Carvalhana S, Oliveira A, Ferreira P, et al. Acute liver failure due to trazodone and diazepam. *GE Port J Gastroenterol* 2017;24:40-2. <https://doi.org/10.1159/000450878>
- ⁸⁴ Torino Medica: (<https://www.torinomedita.it/schede-farmaci/trittico>).
- ⁸⁵ Friedrich MJ. Depression Is the leading cause of disability around the world. *JAMA* 2017;317:1517. <https://doi.org/10.1001/jama.2017.3826>